Ovarian cancer(OC) is the sixth most common cancer in women and the first cause of death between gynecologic malignancies. The 75% of OCs are diagnosed at an advanced stage and no effective prevention is performed. Among the wide spectrum of genomic and immunohistochemical studies on OC biomarkers only Human Epididymis 4 (HE4) seems could improve OC diagnosis if co-detected with CA125. However only few studies on diagnostic accuracy are published and thus a review of available studies for this biomarker should be critical to assess its clinical validity and efficacy. According to available studies no reliable evidences emerged supporting the clinical introduction of this marker, and neither the single nor the parallel marker detection improves the rule out for early and overall OCs.

Evaluation of clinical evidence for the use of HE4 in diagnosis of ovarian cancer (OC) / M. Lanzoni, S. Ferraro, P. Boracchi, E. Biganzoli. ((Intervento presentato al convegno Congresso nazionale della Societa’ Italiana di Biometria (SIB) tenutosi a Gargnano del Garda nel 2011.

Evaluation of clinical evidence for the use of HE4 in diagnosis of ovarian cancer (OC)

M. Lanzoni;P. Boracchi;E. Biganzoli
2011-06-27

Abstract

Ovarian cancer(OC) is the sixth most common cancer in women and the first cause of death between gynecologic malignancies. The 75% of OCs are diagnosed at an advanced stage and no effective prevention is performed. Among the wide spectrum of genomic and immunohistochemical studies on OC biomarkers only Human Epididymis 4 (HE4) seems could improve OC diagnosis if co-detected with CA125. However only few studies on diagnostic accuracy are published and thus a review of available studies for this biomarker should be critical to assess its clinical validity and efficacy. According to available studies no reliable evidences emerged supporting the clinical introduction of this marker, and neither the single nor the parallel marker detection improves the rule out for early and overall OCs.
HE4 ; ovarian cancer ; diagnosis
Settore MED/01 - Statistica Medica
Società Italiana di Biometria
Evaluation of clinical evidence for the use of HE4 in diagnosis of ovarian cancer (OC) / M. Lanzoni, S. Ferraro, P. Boracchi, E. Biganzoli. ((Intervento presentato al convegno Congresso nazionale della Societa’ Italiana di Biometria (SIB) tenutosi a Gargnano del Garda nel 2011.
Conference Object
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/167744
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact